Although methylated MGMT promoter with IDH1 mutant glioblastoma cases showed clinically significant results, the cases with unmethylated MGMT promoter and IDH1 mutation treated with combined chemotherapies had significantly late tumor recurrence. This evidence concerns the gene IDH1 and neoplasm.